Health care · Historical news and closing prices
AdAlta has changed the date of its 2026 annual general meeting from 25 November to 30 November. The meeting will begin at 2pm in Melbourne, with the shareholder letter and notice of meeting due on 30 October.
Closing price · 2026-10-27: $0.004 · +16.67%
AdAlta says the FDA has accepted a pre-IND meeting request for its EW-001 cancer therapy, with advice expected to guide testing and proposed clinical-trial plans; initial Australian manufacturing runs are targeted for the second half of 2026. The company also reported that the first complete responder has passed two years without cancer recurrence, EW-001 received special-access approval in China’s Hainan province, and it received an R&D tax refund, with further funding expected in the December quarter.
Closing price · 2026-10-26: $0.003 · +0.00%